During the last session, Mural Oncology plc (NASDAQ:MURA)’s traded shares were 7.98 million, with the beta value of the company hitting 2.37. At the end of the trading day, the stock’s price was $2.42, reflecting an intraday gain of 0.41% or $0.01. The 52-week high for the MURA share is $4.74, that puts it down -95.87 from that peak though still a striking 60.74% gain since the share price plummeted to a 52-week low of $0.95. The company’s market capitalization is $41.69M, and the average intraday trading volume over the past 10 days was 27.07 million shares, and the average trade volume was 4.46 million shares over the past three months.
Mural Oncology plc (MURA) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 2.00. MURA has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -2.04.
Mural Oncology plc (NASDAQ:MURA) trade information
Mural Oncology plc (MURA) registered a 0.41% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 0.41% in intraday trading to $2.42, hitting a weekly high. The stock’s 5-day price performance is 116.07%, and it has moved by -42.79% in 30 days. Based on these gigs, the overall price performance for the year is -40.83%. The short interest in Mural Oncology plc (NASDAQ:MURA) is 0.59 million shares and it means that shorts have 1.48 day(s) to cover.
While earnings are projected to return 28.50% in 2025, the next five years will return 31.66% per annum.
MURA Dividends
Mural Oncology plc is due to release its next quarterly earnings on 2025-Mar-10. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Mural Oncology plc (NASDAQ:MURA)’s Major holders
Mural Oncology plc insiders own 1.62% of total outstanding shares while institutional holders control 60.57%, with the float percentage being 61.57%. ARMISTICE CAPITAL, LLC is the largest shareholder of the company, while 96.0 institutions own stock in it. As of 2024-06-30, the company held over 1.69 million shares (or 9.9735% of all shares), a total value of $5.3 million in shares.
The next largest institutional holding, with 1.27 million shares, is of SOLAS CAPITAL MANAGEMENT, LLC’s that is approximately 7.4979% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.98 million.
Also, the Mutual Funds coming in first place with the largest holdings of Mural Oncology plc (MURA) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 482.63 shares. This amounts to just over 2.80 percent of the company’s overall shares, with a $1.17 million market value. The same data shows that the other fund manager holds slightly less at 236.78, or about 1.37% of the stock, which is worth about $0.57 million.
